UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16 OR 15d-16 OF
THE SECURITIES EXCHANGE ACT OF 1934
For the month of July, 2013
Commission File No. 000-30082
MERUS LABS INTERNATIONAL INC.
(Translation of registrant's name into English)
470 Granville Street, Suite 503
Vancouver, BC V6C 1V5
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F
Form 20-F
[X] Form 40-F [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1) [ ]
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7) [ ]
- 2 -
SUBMITTED HEREWITH
| Exhibits | |
| 99.1 | Material Change Report dated July 18, 2013 |
| 99.2 | News Release dated June 20, 2013 |
| 99.3 | News Release dated July 9, 2013 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 29, 2013
MERUS LABS INTERNATIONAL INC.
/s/ Andrew Patient
_________________________________________
Andrew Patient
Chief Financial Officer
FORM 51-102F3
MATERIAL CHANGE REPORT
| 1. |
Name and Address of Company |
|
Merus Labs International Inc. (the "Company") | |
| 2. |
Date of Material Change |
|
July 8, 2013 | |
| 3. |
News Release |
|
A press release was disseminated on July 9, 2013 by Marketwire. | |
| 4. |
Summary of Material Change |
|
The Company announced a change in the board of directors. | |
| 5. |
Full Description of Material Change |
|
The Company appointed Mr. Michael Cloutier to the Company's Board of Directors, effective immediately. Mr. Cloutier will serve as an independent non-executive Director. The Board change was facilitated following a request by Mr. Rus to resign from the Board due to health reasons. Mr. David Guebert, a current Director of the Company, will assume the Chairmanship of the Board effective immediately. | |
| 6. |
Reliance on subsection 7.1(2) of National Instrument 51-102 |
|
N/A | |
| 7. |
Omitted Information |
|
None | |
| 8. |
Executive Officer |
|
For further information please contact Andrew Patient, Chief Financial Officer at 416-593-3725 | |
| 9. |
Date of Report |
|
July 18, 2013 |
